Here are five points:
1. Some pharmaceutical companies, like Washington, D.C.-based PhRMA, don’t view the proposal favorably.
2. A PhRMA spokesperson argued price transparency for R&D alludes to future price controls.
3. With rising drugs costs, the idea involves understanding how much it takes to develop a drug to understand how much a company should charge for a drug.
4. Drug companies argue it’s not that simple. The companies consider three factors when pricing a drug: competition, the price consumers will pay and the value patients receive from the drug.
5. Drug companies are paid based on the patient outcomes their drugs provide. To them, focusing on R&D costs is missing the point.
More articles on coding, billing & collections:
National Medical Billing Services Lisa Rock named ‘Top Women Business Owners’ by SBM
Horizon BCBS of New Jersey awards physicians $3M in bonuses — 4 highlights
BCBS considers pulling out of ACA leaving nearly 300,000 North Carolinians hanging in the balance: 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
